ContraFect Corp Employee Directory

Biotechnology ResearchNew York, United States2-10 Employees

ContraFect Corp is a small biotechnology company based in Yonkers, New York, focused on discovering and developing direct lytic agents as new medical modalities for treating life-threatening, antibiotic-resistant infections. The company’s direct lytic agents include lysins and amurin peptides, designed to rapidly kill bacteria, eradicate biofilms, and potentially work in concert with conventional antibiotics. Its product candidates target antibiotic-resistant pathogens such as MRSA and a range of Gram-negative bacteria, with the aim of addressing serious infections such as bacteremia, pneumonia and osteomyelitis.

Exebacase, the lead lysin candidate, has completed a Phase 2 trial for Staphylococcus aureus bacteremia including endocarditis and is advancing in a pivotal Phase 3 program after receiving FDA Breakthrough Therapy designation for MRSA bloodstream infections when used with standard care. A recent development includes ANSM approval to advance Exebacase in prosthetic joint infections, signaling regulatory progress. The company has engaged in collaborations to explore novel lysin candidates, including a research agreement with Rockefeller University.

Sign up for free to view info

Company overview Email format